Treatment of resistance to tepotinib

Tepotinib is indicated as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) who carry mesenchymal-to-epithelial transition factor gene exon 14 (METex14) skipping alterations. In the largest study of its kind involving approximately 300 patients, tepotinib demonstrated strong and durable efficacy in METex14-skip non-small cell lung cancer, achieving an mPFS of 15.3 months and an mOS of 29.7 months in newly diagnosed patients.

Tepotinib is approximately98% protein-bound in plasma, mainly bound to serum albumin and α-1-acid glycoprotein, and is mainly metabolized byCYP3A4 and CYP2C8, with some obvious involvement of unknown UGT enzymes. Metabolite M506 is the major circulating metabolite, accounting for approximately 40.4% of the drug substances observed in plasma. After tepotinibadministration, a total of 10 phase I and phase II metabolites were detected, most of which were excreted in the feces. Patients receiving tepotinib may have their dose reduced, interrupted or discontinued due to adverse reactions. Everyone has a different body constitution and different drug resistance reactions. If you experience any discomfort, please inform your doctor in time.

The original drug of Tepotinib is a new type of drug that is not yet on the market in China and therefore has not been included in the medical insurance. The price of Tepotinib original drug specifications225mg*30 tablets per box listed overseas is around RMB 80,000 (the price may fluctuate due to the exchange rate). It has been on the market for a short time and is expensive. There are also Tepotinib generic drugs produced in other countries. The price of 225mg*60 tablets produced by a Lao pharmaceutical factory is around RMB 8,600 per box (the price may fluctuate due to the exchange rate). The ingredients of generic drugs produced abroad are basically the same as those of the original drug. For specific prices and drug details, please consult Yaode Medical Consultant.